Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activations

The Canadian Cancer Trials Group is pleased to inform you that two trials have recently been activated:

Canadian Cancer Trials Group IND.206 -- A Phase II Study of Sunitinib or Temsirolimus in Patients with Advanced Rare Tumours -- was centrally activated on July 14, 2011.

Canadian Cancer Trials Group NEC.2 (CALGB 80701) -- Randomized Phase II Study of Everolimus alone versus Everolimus plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours -- was centrally activated June 30, 2011.